Immunic (IMUX)

• Market cap: $75.2M
• 1 day: 2.46%
• 5 days: -9.55%
• 1 month: 22.5%
• 3 months: -20.3%
• 6 months: -35%
• Year to date: 7.2%
• 1 year: -38.73%
• 5 years: -96.31%
• 10 years: -99.83%
• Sector: Healthcare
• Industry: Biotechnology

About: Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.

Employees: 90